

Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

February 16, 2024

To,
Asst. Vice President
MSD- Non-Continuous Markets Group
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

Sub: Initial public offering of up to 51,48,800 equity shares of face value of ₹ 10.00 each (the "Equity Shares") of Zenith Drugs Limited (the "Company", and such initial public offering, the "Offer") comprising of Fresh Issue of up to 51,48,800 Equity Shares aggregating up to ₹ 4067.552 Lakhs.

The Board of Directors of the Company at their respective meeting held on February 16, 2024, in consultation with the Book Running Lead Managers to the Issue, has finalized allocation of 12,88,000 Equity Shares, to Anchor Investors at Anchor Investor allocation price of Rs. 79.00 per Equity Share (including share premium of Rs. 69 per Equity Share) in the following manner:

Sr. No.	Name of the Anchor Investor	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)
1	Vikasa India EIF I Fund – Zodiac Global Opportunity Fund	2,11,200	16.40%	79.00
2	Chanakya Opportunities Fund I	1,28,000	9.94%	79.00
3	Moneywise Financial Services Pvt. Ltd	1,28,000	9.94%	79.00
4	Aries Opportunities Fund Limited	2,52,800	19.63%	79.00
5	Neomile Growth Fund – Series I	1,90,400	14.78%	79.00
6	Meru Investment Fund PCC – Cell 1	3,77,600	29.32%	79.00
	Total	12,88,000	100%	

No Mutual Fund have applied through any schemes, scheme-wise details provided in table below:

Sr. No.	Name of Scheme	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)
1	N.A.	N.A.	N.A.	N.A.

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, in case the Issue Price discovered through book building process is higher than the Anchor Investor allocation price, Anchor investors will be required to pay the difference by the pay-in as specified in the revised CAN.

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus.

We request you to make the above information public by disclosing the same on your website.

Thanking you,

Yours faithfully,

**For and on behalf of the Board of
Zenlth Drugs Limited**

**Sandeep Bhardwaj
Managing Director
DIN: 00539347**

Place: Indore